Search

We are Global Top Employer 2024

Global Top Employer certification reflects our impactful people development with high scores in development and steering practices as well as benefits on employee wellbeing.

Our-position

Potential access to selected medications for appropriate patients with serious, life-threatening diseases unable to participate in a clinical trial

Boehringer Ingelheim supports collaboration and knowledge sharing in the livestock industry

Boehringer Ingelheim demonstrates its commitment to farm animal well-being by organising its 11th Expert Forum on Farm Animal Well-Being

BI_X_Shanghai

Boehringer Ingelheim opens a second branch of its digital lab in Shanghai

Boehringer Ingelheim acquires a stake in SoundTalks

Boehringer Ingelheim acquires stake in SoundTalks NV, begins pilot programme

Boehringer Ingelheim half-year results 2023

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

New partnership to develop schizophrenia treatments

Boehringer Ingelheim partners with Sosei Heptares to develop next generation schizophrenia treatments

Rare Diseases: Rare but not alone

We are committed to listen and learn from patients with rare diseases to deliver breakthrough therapies.

inauguration_biopharmaceutical_production_facility_vienna

The state-of-the-art biopharmaceutical production facility in Vienna is the single largest investment in the company's history.

European Election: Europe needs our vote

This week, over 400 million citizens from the 27 European Union (EU) Member States will be able to elect a new European Parliament. Our vote can help to make a better and stronger Europe..

Phase 1 start of treatment for Geographic Atrophy patients

Boehringer initiates Phase 1 evaluation of BI 771716 a treatment for preserving vision of people living with geographic atrophy (GA)

India: Many positive developments for the population

A conversation with interim country manager Sandip Agrawal about a young and growing country

Acquisition Saint-Herblon site and Coophavet brand

Boehringer Ingelheim and Dopharma complete the acquisition of Saint-Herblon production site

A tool to aid in the prevention of African swine fever

ASF COMBAT is an online management and biosecurity assessment tool aimed at reducing the African swine fever introduction risk level.

Major investment for respiratory diseases completed

105 million euros invested into expansion of production facilities in Ingelheim and Dortmund

Partnering with Constantia Flexibles for augmented reality

Boehringer Ingelheim partnered with Constantia Flexibles to provide an innovative packaging solution which enhances the Nutraxin packaging with augmented reality features.

Boehringer Ingelheim leader in hatchery vaccination

Boehringer Ingelheim is a leader in hatchery vaccination with vector vaccines.

Targeting HER2 in cancer: The story of zongertinib

We discovered zongertinib, an HER2 tyrosine kinase inhibitor, being developed as a potential oral treatment for people with HER2-mutated NSCLC

discontinuation-bi-1467335-diabetic-retinopathy

The discontinuation of the development of BI 1467335 in diabetic retinopathy has been announced

Positive results Diabetic Macular Ischemia treatment

HORNBILL Phase I/II study shows positive results for potentially first ever Diabetic Macular Ischemia treatment

Joint venture to fight Antimicrobial Resistance

Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance

Full data chronic kidney disease trial efficacy

Positive full data results announced from the EMPA-KIDNEY Phase III trial in adults with chronic kidney disease